Actavis reported the completion of its acquisition of Allergan Inc. in a cash and equity transaction valued at approximately $70.5 billion. According to Actavis, the combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.
“The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model — Growth Pharma,” Brent Saunders, CEO and President of Actavis, said in a March press release. “Anchored by world-renowned brand franchises, a leading global generics business, a premier pharmaceutical development pipeline and an experienced management team committed to maintaining highly efficient operations across the organization, we are creating an unrivaled foundation for long-term growth. Our combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world.”
Click for more information.